08Jan/13

Veloxis' Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients, the … – FierceDrugDelivery

Veloxis’ Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients, the
FierceDrugDelivery
Non-inferiority was determined by a composite endpoint, measured over a year of follow up that included death, graft failure, biopsy-proven acute rejection or loss to follow-up. Results of this trial demonstrated that patients can be successfully

08Jan/13

Dr. Tandaw Samdarshi – Jackson Free Press

Dr. Tandaw SamdarshiJackson Free PressBased on the pilot, last summer, Samdarshi received a four-year, $3.8 million grant from the National Heart, Lung and Blood Institute to fund the full study. Sleep is a major activity of our lives. If we live to be…